Neoadjuvant immunotherapy has emerged as a promising approach in the treatment of
various malignancies, with preclinical studies showing improved immune responses in the …

Introduction Despite recent developments in the landscape of urothelial carcinoma (UC)
treatment, platinum combination chemotherapy still remains a milestone. Recently …

Glabridin (GLA) has a variety of biological activities and therapeutic effects in cancers.
Whereas the effect of GLA on urothelial bladder carcinoma (UBC) cells and its underlying …

Simple Summary Bladder cancer can be categorized into non-muscle-and muscle-invasive
bladder cancer based on the extent of invasion. While non-muscle-invasive bladder cancer …

Purpose To assess the impact of rural and remote residence on the receipt of guidelines-
recommended treatment, quality of treatment and overall survival (OS) in patients with non …

Background: Bladder cancer (BCA) has high recurrence and metastasis rates, and current
treatment options show limited efficacy and significant adverse effects. It is crucial to find …

Purpose While previous retrospective or phase II studies in Western populations showed
that dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) as …

Background and objective Neoadjuvant chemotherapy (NAC) followed by cystectomy is the
standard of care in muscle-invasive bladder cancer (MIBC). Pathological response has been …

Background Bladder cancer (BC) is an aggressive disease with a poor prognosis. A bladder
tumor, like other malignant neoplasms, is characterized by the presence of both cancer cells …

Improving the chemotherapy sensitivity of bladder cancer is a current clinical challenge. It is
critical to seek out effective combination therapies that include low doses of cisplatin due to …